

Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal)

Technology appraisal guidance

Published: 22 May 2013

www.nice.org.uk/guidance/ta286

Contents

Advice	3
Background.....	4
Information.....	5
Related NICE guidance	5

Advice

NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder because no evidence submission was received from the manufacturer of the technology.

Background

The manufacturer (Alexza Pharmaceuticals) was invited to submit evidence for this single technology appraisal in January 2013.

In January 2013 the manufacturer informed NICE that they would not be making a submission for this appraisal. The manufacturer said that they have received the marketing authorisation for loxapine inhalation (Adusave) but that this restricts administration to adults with mild to moderate agitation associated with schizophrenia and bipolar disorder and to the hospital setting. The manufacturer stated that there is insufficient evidence available to develop the appropriate analytical model required to estimate cost effectiveness in line with NICE single technology appraisal procedures.

NICE has therefore terminated this single technology appraisal.

Information

NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of loxapine inhalation for treating mild to moderate agitation in adults with schizophrenia or bipolar disorder. If, after doing this, organisations still wish to consider loxapine inhalation for treating mild to moderate agitation in adults with schizophrenia or bipolar disorder, they should follow the advice set out in the Department of Health's [Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance](#), which outlines the approach that should be adopted in circumstances where NICE guidance is unavailable.

NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.

Related NICE guidance

For information about NICE guidance that has been issued or is in development, see the [NICE website](#).

- [Core interventions in the treatment and management of schizophrenia in primary and secondary care \(update\)](#). NICE clinical guideline 82 (2009).
- [The management of bipolar disorder in adults, children and adolescents in primary and secondary care](#). NICE clinical guideline 38 (2006).
- [Violence: The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments](#). NICE clinical guideline 25 (2005).

ISBN 978-1-4731-0147-0

Accreditation

